Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel

Molecular Biology Reports

Volumn 38, Issue 3, 2011, Pages 1697-1702

  Jin, Bo ^a   Ni, Huan Chun ^a   Shen, Wei ^a   Li, Jian ^a   Shi, Hai Ming ^a   Li, Yong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Clopidogrel; Coronary artery diseases; CYP2C19; Meta analysis

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19;

ALLELE; ARTERY THROMBOSIS; ARTICLE; BRAIN ISCHEMIA; COHORT ANALYSIS; CORONARY ARTERY DISEASE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RECURRENT DISEASE; STENT THROMBOSIS; WILD TYPE;

ARYL HYDROCARBON HYDROXYLASES; CORONARY ARTERY DISEASE; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; STENTS; STROKE; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 79951581806     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-0282-0     Document Type: Article

References (24)

1. Z Chen G Ma Q Qian Y Yao Y Feng C Tang 2009 Toll-like receptor 8 polymorphism and coronary artery disease Mol Biol Rep 36 1897 1901 1:CAS:528:DC%2BD1MXptV2nurs%3D 10.1007/s11033-008-9396-z 18985439
2. A Var O Utük S Akçali T Sanlidag BS Uyanik G Dinç 2009 Impact of hemostatic gene single point mutations in patients with non-diabetic coronary artery disease Mol Biol Rep 36 2235 2243 1:CAS:528:DC%2BD1MXht1yrs7%2FK 10.1007/s11033-008-9439-5 19123042
3. A Vaisi-Raygani Z Rahimi H Tavilani T Pourmotabbed 2010 Butyrylcholinesterase K variant and the APOE-epsilon 4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients Mol Biol Rep 37 2083 2091 1:CAS:528:DC%2BC3cXis1Wls7g%3D 10.1007/s11033-009- 9666-4 19685167
4. SB King III SC Smith Jr JW Hirshfeld Jr AK Jacobs DA Morrison DO Williams TE Feldman MJ Kern WW O'Neill HV Schaff PL Whitlow CD Adams JL Anderson CE Buller MA Creager SM Ettinger JL Halperin SA Hunt HM Krumholz FG Kushner BW Lytle R Nishimura RL Page B Riegel LG Tarkington CW Yancy 2008 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee Circulation 117 261 295 10.1161/CIRCULATIONAHA.107.188208 18079354
5. VL Serebruany SR Steinhubl PB Berger AI Malinin DL Bhatt EJ Topol 2005 Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 246 251 1:CAS:528:DC%2BD2MXkvFaitg%3D%3D 10.1016/j.jacc.2004. 09.067 15653023 (Pubitemid 40094733)
6. S Matetzky B Shenkman V Guetta M Shechter R Bienart I Goldenberg I Novikov H Pres N Savion D Varon H Hod 2004 Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 3171 3175 1:CAS:528:DC%2BD2cXltVCgtro%3D 10.1161/01.CIR.0000130846.46168.03 15184279
7. W Hochholzer D Trenk HP Bestehorn B Fischer CM Valina M Ferenc M Gick A Caputo HJ Büttner FJ Neumann 2006 Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement J Am Coll Cardiol 48 1742 1750 1:CAS:528:DC%2BD28XhtFOjtb7E 10.1016/j.jacc.2006.06.065 17084243 (Pubitemid 44648629)
8. JL Rehmel JA Eckstein NA Farid JB Heim SC Kasper A Kurihara SA Wrighton BJ Ring 2006 Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450 Drug Metab Dispos 34 600 607 1:CAS:528:DC%2BD28XjtlKnsLo%3D 10.1124/dmd.105.007989 16415119
9. P Gladding M Webster J Ormiston S Olsen H White 2008 Antiplatelet drug nonresponsiveness Am Heart J 155 591 599 1:CAS:528:DC%2BD1cXktVChsb4%3D 10.1016/j.ahj.2007.12.034 18371464 (Pubitemid 351400760)
10. P Gladding M Webster I Zeng H Farrell J Stewart P Ruygrok J Ormiston S El-Jack G Armstrong P Kay D Scott A Gunes ML Dahl 2008 The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial JACC Cardiovasc Interv 1 620 627 10.1016/j.jcin.2008.09.008 19463375
11. LA Malek B Kisiel M Spiewak M Grabowski KJ Filipiak G Kostrzewa Z Huczek R Ploski G Opolski 2008 Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel Circ J 72 1165 1169 1:CAS:528:DC%2BD1cXovFeltrY%3D 10.1253/circj.72.1165 18577829 (Pubitemid 351957086)
12. D Trenk W Hochholzer MF Fromm LE Chialda A Pahl CM Valina C Stratz P Schmiebusch HP Bestehorn HJ Büttner FJ Neumann 2008 Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 1925 1934 1:CAS:528:DC%2BD1cXlvFOqsLY%3D 10.1016/j.jacc.2007.12.056 18482659 (Pubitemid 351636443)
13. JP Collet JS Hulot A Pena E Villard JB Esteve J Silvain L Payot D Brugier G Cayla F Beygui G Bensimon C Funck-Brentano G Montalescot 2009 Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 309 317 1:CAS:528:DC%2BD1MXhtVaqtrY%3D 10.1016/S0140-6736(08)61845-0 19108880
14. B Giusti AM Gori R Marcucci C Saracini I Sestini R Paniccia P Buonamici D Antoniucci R Abbate GF Gensini 2009 Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis Am J Cardiol 103 806 811 1:CAS:528:DC%2BD1MXisl2rtrk%3D 10.1016/j.amjcard.2008.11.048 19268736
15. JL Mega SL Close SD Wiviott L Shen RD Hockett JT Brandt JR Walker EM Antman W Macias E Braunwald MS Sabatine 2009 Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 354 362 1:CAS:528:DC%2BD1MXhtVSlsbs%3D 10.1056/NEJMoa0809171 19106084
16. D Sibbing J Stegherr W Latz W Koch J Mehilli K Dörrler T Morath A Schömig A Kastrati N von Beckerath 2009 Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 916 922 1:CAS:528:DC%2BD1MXkvFKju7s%3D 10.1093/eurheartj/ehp041 19193675
17. T Simon C Verstuyft M Mary-Krause L Quteineh E Drouet N Méneveau PG Steg J Ferrières N Danchin L Becquemont French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators 2009 Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 363 375 1:CAS:528:DC%2BD1MXhtVSlsbY%3D 10.1056/NEJMoa0808227 19106083
18. AR Shuldiner JR O'Connell KP Bliden A Gandhi K Ryan RB Horenstein CM Damcott R Pakyz US Tantry Q Gibson TI Pollin W Post A Parsa BD Mitchell N Faraday W Herzog PA Gurbel 2009 Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 849 857 1:CAS:528:DC%2BD1MXhtVCnt7zL 10.1001/jama.2009.1232 19706858
19. G Feher A Feher G Pusch G Lupkovics L Szapary E Papp 2009 The genetics of antiplatelet drug resistance Clin Genet 75 1 18 1:CAS:528:DC%2BD1MXislOnsr8%3D 10.1111/j.1399-0004.2008.01105.x 19067731
20. R Marcucci AM Gori R Paniccia B Giusti S Valente C Giglioli P Buonamici D Antoniucci R Abbate GF Gensini 2009 Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 237 242 10.1161/CIRCULATIONAHA.108.812636 19118249
21. NF Ford 2009 Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J Clin Pharmacol 49 506 512 1:CAS:528:DC%2BD1MXlsFWmurc%3D 10.1177/ 0091270009332433 19246723
22. JT Brandt SL Close SJ Iturria CD Payne NA Farid CS Ernest 2nd DR Lachno D Salazar KJ Winters 2007 Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2429 2436 1:CAS:528:DC%2BD1cXivFGj 10.1111/j.1538-7836.2007. 02775.x 17900275 (Pubitemid 350154353)
23. C Varenhorst S James D Erlinge JT Brandt OO Braun M Man A Siegbahn J Walker L Wallentin KJ Winters SL Close 2009 Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease Eur Heart J 30 1744 1752 1:CAS:528:DC%2BD1MXptVCjtLw%3D 10.1093/eurheartj/ehp157 19429918
24. DJ Angiolillo A Fernandez-Ortiz E Bernardo F Alfonso C Macaya TA Bass MA Costa 2007 Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 1505 1516 1:CAS:528:DC%2BD2sXjvFGgt7s%3D 10.1016/j.jacc.2006.11.044 17418288 (Pubitemid 46517957)